Tandem Diabetes Care Announces Second Quarter 2023 Financial Results and Updated Full Year 2023 Financial Guidance

Business Wire
16 min read
0
In this article:

SAN DIEGO, August 03, 2023--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2023 and updated its financial guidance for the year ending December 31, 2023.

Second Quarter and Recent Highlights

  • Worldwide installed base increased 16 percent to approximately 437,000 in-warranty customers compared to the second quarter 2022.

  • Commenced U.S. launch of Tandem Source, a data management application designed to be a centralized digital ecosystem for customers and healthcare providers worldwide.

  • Enrolled first participant in pivotal study for people living with type 2 diabetes using Control-IQ technology.

  • Received U.S. Food and Drug Administration clearance for Tandem Mobi, the world’s smallest durable insulin delivery system.

  • $507.2 million in cash, cash equivalents & short-term investments as of June 30, 2023.

"In the second quarter, we demonstrated exceptional progress with our new technology innovations, while driving operational improvements throughout our business and achieving sales expectations," said John Sheridan, president and chief executive officer. "We are navigating 2023 to position Tandem for future growth and long-term success by delivering on the most exciting portfolio in insulin therapy management, while furthering our mission to offer choice and simplified solutions to improve the lives of people with diabetes."

Second Quarter 2023 Financial Results Compared to 2022

In September 2022, the Company began offering the Tandem Choice Program (Tandem Choice) to eligible t:slim X2 customers to provide a pathway to ownership of its newest hardware platform, Tandem Mobi, for a fee when available. As a result of this program, and as previously announced, the Company is providing select financial results for both GAAP and non-GAAP. Additional information, including the accounting treatment of this program and other non-GAAP measures, can be found under the heading "Reconciliation of GAAP versus Non-GAAP Financial Results" in this press release.

Three Months Ended

Six Months Ended

June 30,

June 30,

$ in millions

2023

2023

2022

2023

2023

2022

GAAP

Non-GAAP

GAAP

GAAP

Non-GAAP

GAAP

Pump Shipments

United States

18,964

N/A

20,818

35,967

N/A

39,476

Outside United States

10,530

N/A

11,296

16,582

N/A

20,733

Total Worldwide

29,494

N/A

32,114

52,549

N/A

60,209

Sales

United States

$

142.5

$

144.8

$

145.7

$

273.7

$

278.1

$

277.0

Outside United States

53.4

53.4

54.6

91.6

91.6

99.2

Total Worldwide

$

195.9

$

198.2

$

200.3

$

365.3

$

369.7

$

376.2

  • Gross profit: GAAP gross profit was $101.7 million, compared to $101.9 million. GAAP gross margin was 52 percent, compared to 51 percent.

    Non-GAAP gross profit(1) was $104.0 million. Non-GAAP gross margin(1) was 52 percent.

  • Operating income (loss): GAAP operating loss totaled $38.8 million, or negative 20 percent of sales, compared to operating loss of $12.2 million, or negative 6 percent of sales.

    Non-GAAP operating loss(1) totaled $22.4 million, or negative 11 percent of sales.

    Adjusted EBITDA(1) was $5.3 million, or 3 percent of sales, compared to $11.4 million, or 6 percent of sales.

  • Net income (loss): GAAP net loss(1) was $35.8 million, compared to net loss of $15.1 million.

    Non-GAAP net loss(1) was $19.4 million.

See tables for additional financial information.

2023 Financial Guidance

"The upcoming addition of four new offerings to our portfolio sets a path for renewed momentum as we bring the benefits of Tandem technology to more people living with diabetes worldwide," said Leigh Vosseller, executive vice president and chief financial officer. "In the near-term, we anticipate that our measured rate of market releases has the potential for disruption and reduced sales visibility. We are resetting our guidance to provide our minimum sales expectation for the remainder of the year, while focusing on driving the success of our new offerings and operational efficiencies across the business."

For the year ending December 31, 2023, the Company is updating its 2023 financial guidance as follows:

  • Non-GAAP sales(1) are estimated to be at least $785 million with sales in third quarter of at least $190 million.

    • Sales inside the United States of at least $575 million with sales in the third quarter of at least $135 million.

    • Sales outside the United States of at least $210 million with sales in the third quarter of at least $55 million.

  • Non-GAAP gross margin(1) is estimated to be approximately 51 percent.

  • Adjusted EBITDA margin(1) is estimated to be at least breakeven as a percent of sales.

    • Includes approximately 3 percent from the impact of operating costs associated with the acquisitions of Capillary Biomedical and AMF Medical.

  • Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $110 million. This includes:

    • Approximately $95 million non-cash, stock-based compensation expense.

    • Approximately $15 million depreciation and amortization expense.

(1)

A reconciliation of non-GAAP financial measures to their closest GAAP equivalent and additional information can be found in Table E and under the heading "Reconciliation of GAAP versus Non-GAAP Financial Results."

Non-GAAP Financial Measures

Certain non-GAAP financial measures are presented in this press release to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important operating performance indicators because they exclude items that are unrelated to, and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. To the extent the Company uses such non-GAAP financial measures in the future, they will be calculated using a consistent method from period to period. A reconciliation of each of the GAAP financial measures to the most directly comparable non-GAAP financial measures has been provided in Table E "Reconciliation of GAAP versus Non-GAAP Financial Results" attached to this press release.

In particular, the accounting treatment for Tandem Choice has a high degree of complexity. In September 2022 when the program was launched, the Company began deferring a portion of sales for each eligible t:slim X2 pump shipped in the United States. Such deferrals will be recognized on a customer-by-customer basis following the commercial launch of the Company’s new hardware platform, Tandem Mobi. The timing of recognition will be based on either a) an affirmative election to participate in Tandem Choice or b) expiration of the right to participate. Notably:

  • Offering the program does not impact the economics associated with how or when the initial pump sale is reimbursed.

  • Customer eligibility is automatic and no election is necessary to participate in Tandem Choice at the time of a t:slim X2 purchase. An affirmative election is only required when the new hardware platform, Tandem Mobi, is commercially available, at which time any customer fees will be received and recognized as a sale.

  • The expiration date of Tandem Choice is December 31, 2024.

Consistent with SEC regulations, the Company has not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the "unreasonable efforts" exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that may be made to the Company’s GAAP financial measures in calculating the non-GAAP financial measures.

Conference Call

The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days. To access the call by phone, please use this link (https://register.vevent.com/register/BIb61cfe435b0f43f5a67b990141f26d3d) and you will be provided with dial-in details, including a personal pin.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company headquartered in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results and the ability to achieve other operational and commercial goals for this year, including the launch of multiple new products. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s existing products and products under development; products marketed and sold or under development by competitors; the Company’s ability to establish and sustain operations to support international sales, including expanding into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to complete the development and launch of new products when anticipated; risks associated with the regulatory approval process for new products; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete, less desirable; or may otherwise negatively impact the purchasing trends of customers; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; and other risks identified in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

TANDEM DIABETES CARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

Table A

(in thousands)

(Unaudited)

June 30,

December 31,

2023

2022

Assets

Current assets:

Cash, cash equivalents and short-term investments

$

507,246

$

616,901

Accounts receivable, net

98,714

114,717

Inventories

147,599

111,117

Other current assets

10,745

7,241

Total current assets

764,304

849,976

Property and equipment, net

73,752

68,552

Operating lease right-of-use assets

91,054

110,626

Other long-term assets

17,566

23,631

Total assets

$

946,676

$

1,052,785

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable, accrued expenses and employee-related liabilities

$

105,673

$

104,007

Operating lease liabilities

17,757

13,121

Deferred revenue

23,401

18,837

Other current liabilities

27,824

29,325

Total current liabilities

174,655

165,290

Convertible senior notes, net - long-term

284,128

283,232

Operating lease liabilities - long-term

118,400

123,524

Deferred revenue - long-term

15,305

16,874

Other long-term liabilities

24,954

23,918

Total liabilities

617,442

612,838

Total stockholders’ equity

329,234

439,947

Total liabilities and stockholders’ equity

$

946,676

$

1,052,785

TANDEM DIABETES CARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Table B

(in thousands, except per share data)

(Unaudited)

Three Months Ended
June 30,

Six Months Ended
June 30,

2023

2022

2023

2022

Sales

$

195,917

$

200,262

$

365,300

$

376,169

Cost of sales

94,182

98,316

180,658

183,130

Gross profit

101,735

101,946

184,642

193,039

Operating expenses:

Selling, general and administrative

97,610

80,614

187,424

153,885

Research and development

42,933

33,571

85,093

66,731

Acquired in-process research and development expenses

—

—

78,750

—

Total operating expenses

140,543

114,185

351,267

220,616

Operating loss

(38,808

)

(12,239

)

(166,625

)

(27,577

)

Total other income (expense), net

4,179

(711

)

8,410

(1,812

)

Loss before income taxes

(34,629

)

(12,950

)

(158,215

)

(29,389

)

Income tax expense

1,146

2,106

1,433

382

Net loss

$

(35,775

)

$

(15,056

)

$

(159,648

)

$

(29,771

)

Net loss per share - basic

$

(0.55

)

$

(0.23

)

$

(2.47

)

$

(0.47

)

Net loss per share - diluted

$

(0.55

)

$

(0.24

)

$

(2.47

)

$

(0.47

)

Weighted average shares used to compute basic and net loss per share

64,830

64,077

64,690

63,979

Weighted average shares used to compute diluted net loss per share

64,830

64,078

64,690

63,980

TANDEM DIABETES CARE, INC.

SALES BY GEOGRAPHY

Table C(1)

(Unaudited)

($'s in thousands)

Three Months Ended
June 30,

Six Months Ended
June 30,

2023

2022

% Change

2023

2022

% Change

United States:

Pump

$

74,360

$

81,656

(9

)%

$

140,816

$

155,153

(9

)%

Supplies and other

70,450

64,011

10

%

137,259

121,797

13

%

Deferral for Tandem Choice

(2,309

)

—

—

%

(4,332

)

—

—

%

Total GAAP Sales in the United States

$

142,501

$

145,667

(2

)%

$

273,743

$

276,950

(1

)%

Adjustment for Tandem Choice

2,309

—

—

%

4,332

—

—

%

Total Non-GAAP Sales in the United States

$

144,810

$

145,667

(1

)%

$

278,075

$

276,950

—

%

Outside the United States:

Pump

$

27,317

$

25,798

6

%

$

45,563

$

48,130

(5

)%

Supplies and other

26,099

28,797

(9

)%

45,994

51,089

(10

)%

Total Sales Outside the United States

$

53,416

$

54,595

(2

)%

$

91,557

$

99,219

(8

)%

Total GAAP Worldwide Sales

$

195,917

$

200,262

(2

)%

$

365,300

$

376,169

(3

)%

Adjustment for Tandem Choice

2,309

—

—

%

4,332

—

—

%

Total Non-GAAP Worldwide Sales

$

198,226

$

200,262

(1

)%

$

369,632

$

376,169

(2

)%

(1)

A reconciliation of non-GAAP financial measures to their closest GAAP equivalent and additional information can be found in Table E and under the heading "Reconciliation of GAAP versus Non-GAAP Financial Results."

TANDEM DIABETES CARE, INC.

PUMP SHIPMENTS

Table D

Three Months Ended
June 30,

Six Months Ended
June 30,

2023

2022

% Change

2023

2022

% Change

Pumps Shipped:

United States

18,964

20,818

(9

)%

35,967

39,476

(9

)%

Outside the United States

10,530

11,296

(7

)%

16,582

20,733

(20

)%

Total Pumps Shipped

29,494

32,114

(8

)%

52,549

60,209

(13

)%

TANDEM DIABETES CARE, INC.

Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited)

Table E

($'s in thousands)

Three Months Ended
June 30,

Six Months Ended
June 30,

2023

2022

2023

2022

GAAP sales

$

195,917

$

200,262

$

365,300

$

376,169

Adjustment for Tandem Choice (1)

2,309

—

4,332

—

Non-GAAP sales

$

198,226

$

200,262

$

369,632

$

376,169

GAAP gross profit

$

101,735

$

101,946

$

184,642

$

193,039

Adjustment for Tandem Choice(1)

2,309

—

4,332

—

Non-GAAP gross profit

$

104,044

$

101,946

$

188,974

$

193,039

Non-GAAP gross margin(2)

52

%

51

%

51

%

51

%

GAAP operating loss

$

(38,808

)

$

(12,239

)

$

(166,625

)

$

(27,577

)

Acquired in-process research and development(3)

—

—

78,750

—

Non-recurring facility consolidation costs(4)

14,099

—

14,099

—

Severance costs - cash and noncash

—

—

2,680

—

Adjustment for Tandem Choice(1)

2,309

—

4,332

—

Non-GAAP operating loss

$

(22,400

)

$

(12,239

)

$

(66,764

)

$

(27,577

)

Non-GAAP operating margin(2)

(11

)%

(6

)%

(18

)%

(7

)%

GAAP net loss

$

(35,775

)

$

(15,056

)

$

(159,648

)

$

(29,771

)

Income tax expense

1,146

2,106

1,433

382

Interest income and other, net

(5,784

)

(826

)

(11,649

)

(1,241

)

Interest expense

1,605

1,537

3,239

3,053

Depreciation and amortization

4,265

3,553

7,661

7,181

Stock-based compensation expense

23,400

20,131

44,205

38,241

Acquired in-process research and development(3)

—

—

78,750

—

Non-recurring facility consolidation costs(4)

14,099

—

14,099

—

Severance costs - cash and noncash

—

—

2,680

—

Adjustment for Tandem Choice(1)

2,309

—

4,332

—

Adjusted EBITDA

$

5,265

$

11,445

$

(14,898

)

$

17,845

Adjusted EBITDA margin(2)

3

%

6

%

(4

)%

5

%

GAAP net loss

$

(35,775

)

$

(15,056

)

$

(159,648

)

$

(29,771

)

Acquired in-process research and development(3)

—

—

78,750

—

Non-recurring facility consolidation costs(4)

14,099

—

14,099

—

Severance costs - cash and noncash

—

—

2,680

—

Adjustment for Tandem Choice(1)

2,309

—

4,332

—

Non-GAAP net loss

$

(19,367

)

$

(15,056

)

$

(59,787

)

$

(29,771

)

(1)

The accounting treatment for Tandem Choice has a high degree of complexity. Additional information can be found under the heading "Non-GAAP Financial Measures."

(2)

Non-GAAP margins including non-GAAP gross margin, non-GAAP operating margin, and adjusted EBITDA margin are calculated using non-GAAP sales.

(3)

The Company recorded a $78.8 million charge representing the value of acquired in-process research and development assets with no alternative future use and acquisition related expenses.

(4)

The Company recorded $14.1 million of facility consolidation costs related to our Vista Sorrento lease in San Diego, California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230803082124/en/

Contacts

Media Contact:
858-255-6388
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Advertisement

Recommended Stories